| WB | 1/500-1/1000 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/50-1/100 | Human,Mouse,Rat |
| ICC | 1/50-1/200 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | FOXA1; Forkhead box A1; Forkhead box protein A1; HNF-3-alpha; TCF3A; HNF3A; Transcription factor 3A |
| Entrez GeneID | 3169 |
| WB Predicted band size | Calculated MW: 49 kDa; Observed MW: 49 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human,Mouse,Rat |
| Immunogen | A synthesized peptide derived from human FOXA1 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide. |
+ +
以下是3-4篇关于FOXA1抗体的参考文献(示例为虚构内容，基于常见研究方向概括)：
1. **文献名称**：*FOXA1 Antibody Validation in Hormone Receptor-Positive Breast Cancer*
**作者**：Smith, J. et al.
**摘要**：验证FOXA1抗体在乳腺癌组织中的特异性，通过免疫组化(IHC)和Western blot分析，证实其可用于检测FOXA1蛋白表达水平，并发现其与雌激素受体(ER)信号通路的相关性。
2. **文献名称**：*FOXA1 as a Pioneer Factor in Prostate Cancer: Antibody Application in ChIP-seq Studies*
**作者**：Wang, L. et al.
**摘要**：利用FOXA1抗体进行染色质免疫沉淀测序(ChIP-seq)，揭示了FOXA1在前列腺癌细胞中作为“先驱因子”调控雄激素受体(AR)结合的分子机制。
3. **文献名称**：*Development of a High-Specificity Monoclonal FOXA1 Antibody for Diagnostic Use*
**作者**：Garcia, R. et al.
**摘要**：报道了一种新型FOXA1单克隆抗体的开发与验证，证明其在多种癌症(如乳腺癌、胰腺癌)组织中的高灵敏度和特异性，适用于临床病理诊断。
4. **文献名称**：*FOXA1 Expression and Prognostic Significance in Triple-Negative Breast Cancer*
**作者**：Chen, Y. et al.
**摘要**：通过FOXA1抗体免疫组化分析三阴性乳腺癌(TNBC)样本，发现FOXA1低表达与患者不良预后相关，提示其潜在生物标志物作用。
(注：以上文献为示例，实际引用时请通过PubMed等数据库检索真实文献。)
FOXA1 (Forkhead Box A1) antibody is a key tool in studying the FOXA1 protein, a transcription factor critical for organ development and cellular differentiation. FOXA1. also known as hepatocyte nuclear factor 3-beta (HNF3β), belongs to the forkhead box family, characterized by a conserved DNA-binding "forkhead" domain. It acts as a pioneer factor, modifying chromatin structure to enable other transcription factors to access DNA, playing essential roles in hormone-responsive tissues like the breast, prostate, and liver.
In research, FOXA1 antibodies are widely used in techniques such as Western blotting, immunohistochemistry (IHC), and chromatin immunoprecipitation (ChIP) to detect FOXA1 expression, localization, and DNA-binding activity. These antibodies help investigate FOXA1's role in gene regulation, particularly in estrogen receptor (ER)- and androgen receptor (AR)-signaling pathways. Dysregulation of FOXA1 is implicated in cancers, including hormone-dependent breast and prostate cancers, where it often serves as a prognostic biomarker. For example, FOXA1 overexpression in ER-positive breast cancer correlates with luminal subtype classification, while in prostate cancer, it drives oncogenic programs by interacting with AR.
FOXA1 antibodies also aid in exploring its dual role as a tumor suppressor or promoter, depending on cellular context. Recent studies highlight its involvement in epigenetic remodeling and lineage-specific oncogenesis, making it a potential therapeutic target. Validated FOXA1 antibodies are essential for both basic research and clinical diagnostics, supporting advances in precision oncology and molecular pathology.
×
